Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other financing activities (2016 - 2022)

Cumberland Pharmaceuticals' Other financing activities history spans 13 years, with the latest figure at -$370464.0 for Q1 2022.

  • For Q1 2022, Other financing activities fell 232.3% year-over-year to -$370464.0; the TTM value through Mar 2022 reached -$650484.0, down 409.86%, while the annual FY2020 figure was $135405.0, 86.46% down from the prior year.
  • Other financing activities for Q1 2022 was -$370464.0 at Cumberland Pharmaceuticals, up from -$632646.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.0 million in Q3 2019 and bottomed at -$800000.0 in Q2 2019.
  • The 5-year median for Other financing activities is $160819.0 (2020), against an average of $78790.9.
  • The largest annual shift saw Other financing activities soared 181.39% in 2021 before it plummeted 232.3% in 2022.
  • A 5-year view of Other financing activities shows it stood at -$248108.0 in 2018, then soared by 481.89% to $947500.0 in 2019, then crashed by 170.82% to -$670985.0 in 2020, then grew by 5.71% to -$632646.0 in 2021, then skyrocketed by 41.44% to -$370464.0 in 2022.
  • Per Business Quant, the three most recent readings for CPIX's Other financing activities are -$370464.0 (Q1 2022), -$632646.0 (Q4 2021), and $452536.0 (Q3 2021).